>
Compumedics logo

CMP - Compumedics Share Price

A$0.37 0.0  0.0%

Last Trade - 18/06/21

Sector
Healthcare
Size
Micro Cap
Market Cap £35.6m
Enterprise Value £35.2m
Revenue £18.9m
Position in Universe 1029th / 1914
Bullish
Bearish
Unlock CMP Revenue
Momentum
Relative Strength (%)
1m -15.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -36.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
33.5 37.5 34.4 37.0 41.5 35.1 37.4 54.5 +0.9%
+120.2 +61.6 -62.0 +113.2 +44.3 +333.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020,Compumedics Limited revenues decreased 1% to A$18M. Netincome increased from A$161K to A$1.3M. Revenues reflectUSA segment decrease of 16% to A$5.3M, Australia and AsiaPacific segment decrease of 8% to A$7.4M, USA segmentdecrease of 16% to A$5.3M, Australia & Asia Pacific segmentdecrease of 8% to A$7.4M. Net income reflects Other revenueincrease from A$206K to A$890K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CMP Revenue Unlock CMP Revenue

Net Income

CMP Net Income Unlock CMP Revenue

Normalised EPS

CMP Normalised EPS Unlock CMP Revenue

PE Ratio Range

CMP PE Ratio Range Unlock CMP Revenue

Dividend Yield Range

CMP Dividend Yield Range Unlock CMP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CMP EPS Forecasts Unlock CMP Revenue
Profile Summary

Compumedics Limited is engaged in the research, development, manufacture and distribution of medical equipment. The Company's segments include USA, Australia and Asia Pacific, and Europe. The USA business includes the United States, Canada and Latin America. The Australia and Asia Pacific segment includes all countries in the Asia Pacific region. The Europe segment includes all countries in the European region, and all Middle Eastern countries. It sells all of its product offerings, including sleep diagnostic systems, clinical electroencephalogram (EEG) systems, brain monitoring systems, ultra sonic blood-flow systems, supplies and technical service and support. The USA business also includes that sleep diagnostic services business. Its product, Somfit, is a fitness tracker. The Somfit tracks the user's sleep, collecting medical grade data to provide true sleep insights. The Company also focuses on the development of neurodiagnostic, Neuroscan research and consumable businesses.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated September 30, 1987
Public Since December 21, 2000
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 177,162,948
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CMP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CMP
Upcoming Events for CMP
Monday 30th August, 2021 Estimate
Full Year 2021 Compumedics Ltd Earnings Release
Frequently Asked Questions for Compumedics
What is the Compumedics share price?

As of 18/06/21, shares in Compumedics are trading at A$0.37, giving the company a market capitalisation of £35.6m. This share price information is delayed by 15 minutes.

How has the Compumedics share price performed this year?

Shares in Compumedics are currently trading at A$0.37 and the price has moved by -13.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Compumedics price has moved by -31.7% over the past year.

What are the analyst and broker recommendations for Compumedics?

Of the analysts with advisory recommendations for Compumedics, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Compumedics is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Compumedics next release its financial results?

Compumedics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Compumedics dividend yield?

Compumedics does not currently pay a dividend.

Does Compumedics pay a dividend?

Compumedics does not currently pay a dividend.

When does Compumedics next pay dividends?

Compumedics does not currently pay a dividend.

How do I buy Compumedics shares?

To buy shares in Compumedics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Compumedics?

Shares in Compumedics are currently trading at A$0.37, giving the company a market capitalisation of £35.6m.

Where are Compumedics shares listed? Where are Compumedics shares listed?

Here are the trading details for Compumedics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: CMP
What kind of share is Compumedics?

Based on an overall assessment of its quality, value and momentum, Compumedics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Compumedics share price forecast 2021?

Shares in Compumedics are currently priced at A$0.37. At that level they are trading at 0.17% discount to the analyst consensus target price of 0.00.

Analysts covering Compumedics currently have a consensus Earnings Per Share (EPS) forecast of 0.009 for the next financial year.

How can I tell whether the Compumedics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Compumedics. Over the past six months, the relative strength of its shares against the market has been -26.19%. At the current price of A$0.37, shares in Compumedics are trading at -15.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Compumedics PE Ratio?

We were not able to find PE ratio data for Compumedics.

Who are the key directors of Compumedics?

Compumedics's management team is headed by:

David Burton - CHM
Alan Anderson - NED
Graham Mitchell - NID
Warwick Freeman - CTO
David Lawson - CFO
Christoph Witte - OTH
Kerry Hubick - OTH
Rob Ferguson - GMG
Tucson Dunn - DRC
Who are the major shareholders of Compumedics?

Here are the top five shareholders of Compumedics based on the size of their shareholding:

Burton (David) Individual Investor
Percentage owned: 55.34% (98.0m shares)
Beijing Bestmed Tech. Ltd. Corporation
Percentage owned: 2.77% (4.90m shares)
Medigas Italia S.R.L Corporation
Percentage owned: 2.45% (4.33m shares)
Lawson (David Francis) Individual Investor
Percentage owned: 1.96% (3.47m shares)
B & R James Investments Pty. Ltd. Corporation
Percentage owned: 1.41% (2.50m shares)
Similar to CMP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.